Doris Molina-Henry, PhD

Dr. Doris Molina‐Henry is an Assistant Professor of Research Neurology at the USC Keck School of Medicine Alzheimer’s Therapeutic Research Institute. Her work is focused on the science of recruitment and retention of diverse participants into clinical trials. Currently, she works on evaluating strategies that promote participation of cognitively unimpaired, at-risk, diverse adults into studies that aim to help prevent the symptoms of Alzheimer’s well before they begin. She received a PhD in Neurobiology and Anatomy from Wake Forest University School of Medicine.

Recent Work

Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease

Differential eligibility may contribute to underrepresentation of some minoritized racial and ethnic groups in early AD trials. Amyloid biomarker eligibility is a requirement to confirm the diagnosis of AD and for treatment with amyloid-lowering drugs and differed among racial and ethnic groups.
Categorized in

Doris Molina-Henry, PhD's Bio

Recent Work

Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease